The potential therapeutic targets currently being considered for MI-CS patients include but are not limited to IL-6 [51], complement components [52], dipeptidyl peptidase-3 (DPP-3) [53], and C-reactive protein [54]. The gene discussed is IL6; the disease is Cowden syndrome 1.